ArticleNature communications2021
Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Diagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations.European heart journal. Quality of care & clinical outcomes · 2025Pooled it
- Integrating delivery systems and microenvironmental cues to accelerate clinical translation of cardiac reprogramming.Materials today. Bio · 2026Review
- Mitochondrial heterogeneity across cardiac cell types in heart failure with preserved ejection fraction.Redox biology · 2026Review
- Mitochondrial protein OPA3 sustains cardiac function by regulating calcium handling in male mice.Nature communications · 2026Article
- Plasma proteomics stratification identifies phospholamban R14del carriers at risk for disease progression.Cardiovascular research · 2026Article
- The Pivotal Role of Plant Derivatives and Eicosanoid Signaling Modulation in Counteracting Cardiomiopathy.International journal of molecular sciences · 2026Review
- Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy.Signal transduction and targeted therapy · 2026Article
- Early fibrotic gene activation precedes structural remodeling in the heart of cardiac myosin binding protein-C knockout mice.Physiological genomics · 2026Article
- RNA-Based Therapies for Treating Monogenic Cardiomyopathies.The Canadian journal of cardiology · 2026Review
- Emerging Mechanisms and Therapeutic Strategies in Dilated Cardiomyopathy.Biomedicines · 2026Review
- The SERCA-PLN-DWORF axis in cardiometabolic disease: mechanisms and therapeutic perspectives.Cardiovascular diabetology · 2025Review
- RNA Therapeutics in Heart Failure.Journal of cardiovascular translational research · 2025Review
- Calcium handling remodeling in dilated cardiomyopathy: From molecular mechanisms to targeted therapies.Channels (Austin, Tex.) · 2025Review
- LMNA-related cardiomyopathy: From molecular pathology to cardiac gene therapy.Journal of advanced research · 2025Review
- RNA chemistry and therapeutics.Nature reviews. Drug discovery · 2025Review
- In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment.Cardiovascular research · 2025Article
- Tailored therapeutics for cardiomyopathies.Nature reviews. Cardiology · 2025Review
- Targeting Calcium Regulation for Heart Failure and Arrhythmia Therapeutics: A Critical Review.Circulation · 2025Review
- Integrative Approaches to Myopathies and Muscular Dystrophies: Molecular Mechanisms, Diagnostics, and Future Therapies.International journal of molecular sciences · 2025Review
- Emerging roles for microproteins as critical regulators of endoplasmic reticulum function and cellular homeostasis.Seminars in cell & developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 8 institutions in 7 countries.
Niels Grote Beverborg *Department of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-4629-9960
Daniela Später *Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. daniela.spaeter@astrazeneca.com.ORCID 0000-0002-5398-1784
Ralph Knöll *Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0001-8871-112X
Alejandro HidalgoBioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Steve T YehIonis Pharmaceuticals, Carlsbad, CA, USA.
Zaher ElbeckIntegrated Cardio Metabolic Center (ICMC), Karolinska Institutet, Huddinge, Sweden.ORCID 0000-0002-2073-7988
Herman H W SilljéDepartment of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-3292-6302
Tim R EijgenraamDepartment of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0001-8843-9656
Humam SigaIntegrated Cardio Metabolic Center (ICMC), Karolinska Institutet, Huddinge, Sweden.
Magdalena ZurekBioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Malin PalmérBioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Susanne PehrssonBioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Tamsin AlberyBioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Nils BomerDepartment of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0001-5926-6960
Martijn F HoesDepartment of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-0234-438X
Cornelis J BoogerdDepartment of Molecular Cardiology, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-7119-5381
Michael FriskInstitute for Experimental Medical Research, Oslo University Hospital and KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway.ORCID 0000-0001-9430-7908
Eva van RooijDepartment of Molecular Cardiology, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-2026-9408
Sagar DamleIonis Pharmaceuticals, Carlsbad, CA, USA.
William E LouchInstitute for Experimental Medical Research, Oslo University Hospital and KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway.
Qing-Dong WangBioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0001-9570-4411
Regina Fritsche-DanielsonBioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Kenneth R ChienIntegrated Cardio Metabolic Center (ICMC), Karolinska Institutet, Huddinge, Sweden.ORCID 0000-0002-2759-8378
Kenny M HanssonBioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Adam E MullickIonis Pharmaceuticals, Carlsbad, CA, USA. AMullick@ionisph.com.ORCID 0000-0003-4600-961X
Rudolf A de BoerDepartment of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-4775-9140
Peter van der MeerDepartment of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. p.van.der.meer@umcg.nl.ORCID 0000-0002-9705-4413
AstraZeneca (Sweden) · SEUniversity Medical Center Groningen · NLKarolinska Institutet · SEIonis Pharmaceuticals (United States) · USOslo University Hospital · NORoyal Netherlands Academy of Arts and Sciences · NLIntegrated Cardio Metabolic Centre · SEThe University of Melbourne · AU
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a major cause of morbidity and mortality worldwide, highlighting an urgent need for novel treatment options, despite recent improvements. Aberrant Ca
Indexed as
Genetic TherapyAnimalsCalciumCalcium-Binding ProteinsCardiomyopathiesFemaleHeart FailureHumansMaleMiceMice, Inbred C57BLMyocytes, CardiacOligonucleotides, AntisensePhospholambanRatsRats, Inbred LewCalciumCalcium-Binding ProteinsOligonucleotides, AntisensePhospholamban
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.